Common use of Research Strategy Clause in Contracts

Research Strategy. The CRADA Parties will build upon the hypothesis that the EC/CB1R system and iNOS are both pro-fibrogenic, and combined inhibition of these targets by a single compound would improve therapeutic outcome in scleroderma. Parties plan to test the novel dual-target compound MRI-1867 in different [ ] of scleroderma such as the [ ] Subcutaneous injections of [ ] induce skin and pulmonary fibrosis (40), quantifiable histologically and biochemically. A recent modification in this protocol generated reproducible and more homogenous skin and lung fibrosis lesions mimicking human SSc, with interstitial lung disease-like manifestations (41). This latter approach will be used in these proposed studies. [ ] a well-established and widely used genetic model of SSc, featuring many skin abnormalities similar to those observed in human disease (40, 42). Using these two experimental models will establish the therapeutic potential of these dual-target compounds. Specific Aim 1: Test the target-specificity of hybrid peripheral CB1R/iNOS inhibitors by [ ]using the subcutaneous [ ] This approach would help to evaluate the relative contribution of the two targets to the therapeutic efficacy of the hybrid inhibitor.